Daily Oral PCSK9 Inhibitor Encouraging in Phase 1 Trials

What if the cholesterol-crushing efficacy of current PCSK9 inhibitors came in a pill instead of a syringe? That's one possibility for a Merck agent in the earliest stages of human trials.

Related Keywords

Kenilworth ,New Jersey ,United States ,Washington University ,Missouri ,American ,Annec Goldberg ,Douglasg Johns ,Sanofi Regeneron ,Amgen ,American Heart Association ,European Union ,Washington University School Of Medicine ,Novartis ,Scientific Sessions ,Washington University School ,Lipids ,Ipid Management ,Pcsk9 ,Roprotein Convertase Subtilisin Kexin Type 9 ,Hyperlipidemia ,Nucleoside Reverse Transcriptase Inhibitors ,Ucleoside Analog ,Artis ,Nhibitor Nucleoside Reverse Transcriptase ,Translational Research ,Ranslative Research ,Translational Science ,Clinical Research ,Clinical Trials ,Linical Studies ,Cv ,Ardiovascular ,Low Ldl Cholesterol ,Ypobetalipoproteinemi ,